News

Breakthrough Study Shows Plogosertib Potential for BTC Treatment

Breakthrough Study Shows Plogosertib Potential for BTC Treatment

Plogging New Paths for Biliary Tract Cancer Treatment

- Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis -

KUALA LUMPUR, Malaysia — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC; NASDAQ: CYCCP), a dynamic biopharmaceutical company focused on pioneering cancer treatments, has spotlighted a preclinical study conducted by independent researchers. Titled, “Evaluation of antitumor effects of plogosertib, PLK1 inhibitor in biliary tract cancer with BUBR1 as a potential biomarker”, this study showcases findings from the journal, Cancer Research, initially presented at a significant cancer research gathering this year.

The study uncovered that several BTC cell lines demonstrated sensitivity to the compound plogosertib, both when used alone and in combination with other treatments. This aligns with plogosertib's role as an antimitotic agent, which promotes the formation of the mitotic checkpoint complex (MCC) during prometaphase. The end result? Induced mitotic arrest and subsequent apoptosis of malignant BTC cells.

BUBR1: A Potential Biomarker

Researchers also identified BUBR1, a vital protein for the mitotic checkpoint, as a possible biomarker that can help gauge the effectiveness of plogosertib. Notably, BTC cells exhibiting high levels of BUBR1 showed greater sensitivity to plogosertib than those with lower expressions. This crucial finding posits that BTC cells with elevated BUBR1 levels are more likely to respond positively to the PLK1 inhibitor, especially when paired with ATR inhibitors. This opens avenues for strategic combination therapies targeting PLK1 in treating BTC.

Understanding Biliary Tract Cancer

Biliary tract cancer (BTC), or cholangiocarcinoma, is a rare yet aggressive cancer affecting the biliary system, the intricate network connecting the liver, gallbladder, and small intestine. According to estimates from cancer health agencies, the annual incidence of BTC in the U.S. is around 4.4 cases per 100,000 people. Sadly, the prognosis for BTC patients remains grim, with approximately only 10-40% being alive five years post-surgery.

Treatment avenues for BTC can vary, including chemotherapy, surgery, radiation, and targeted therapies, depending on the stage of the disease and its location. Despite these strategies, effective cures are scarce, leading to an urgent need for innovative treatments for patients grappling with recurrent, refractory, or unresectable BTC.

Plogo's Mechanism: How It Works

The polo-like kinase 1 (PLK1) plays a crucial role in cell division. As a serine/threonine kinase, it is a key regulator involved in critical processes such as DNA damage response, spindle formation, and cell division. Cancer cells, particularly those mutated in KRAS or p53, exhibit heightened sensitivity to PLK1 depletion. Conversely, normal cells with functional cell cycle checkpoints show resilience against these treatments.

Plogosertib (formerly known as CYC140) stands out as a novel compounds that selectively inhibits PLK1. It has showcased remarkable efficacy in human tumor xenograft models without toxic side effects at the administered doses. Cyclacel’s commitment to advancing plogosertib in both solid tumors and leukemias is supported by encouraging preclinical evidence indicating effectiveness in cancers with specific mutations. Recent findings also hint at its potential effectiveness against KRAS-mutated colorectal cancer, elevating its profile in the oncology landscape.

Exciting Clinical Developments

Preliminary data from a Phase 1 clinical study of oral plogosertib illustrated excellent tolerability among participants, with no dose-limiting toxicities observed across five different dosing schedules. Clinical benefits were documented in patients battling various cancers, including adenoid cystic carcinoma, BTC, ovarian malignancies, and squamous cell cancers.

Cyclacel's Vision for the Future

Cyclacel is on a mission to innovate within the oncology sector. As a clinical-stage biopharmaceutical entity, it is dedicated to developing state-of-the-art cancer therapies grounded in cell cycle and mitotic biology. The firm is concentrating on its anti-mitotic program, assessing the efficacy of plogosertib in solid tumors and hematological cancers. With a robust pipeline featuring cutting-edge drug candidates, Cyclacel seeks to establish a diversified biopharmaceutical enterprise addressing key oncology and hematology indications.

For more details about Cyclacel’s development endeavors and product offerings, interested parties can visit www.cyclacel.com.

Frequently Asked Questions

What is Plogosertib and how does it work?

Plogosertib is a selective PLK1 inhibitor that induces apoptosis in cancer cells by causing prolonged mitotic arrest.

What is the significance of the BUBR1 protein?

BUBR1 serves as a potential biomarker for assessing the sensitivity of BTC cells to Plogosertib, helping to personalize treatment strategies.

What does the future hold for Cyclacel Pharmaceuticals?

Cyclacel aims to advance its pipeline of innovative cancer medicines that leverage understanding of cell cycle dynamics and mitotic processes.

What are the current treatment options for biliary tract cancer?

BTC treatment can include chemotherapy, surgery, radiation, and targeted therapies, though effective options for advanced cases are limited.

How has Plogosertib performed in clinical trials?

Phase 1 trials indicate that Plogosertib is well tolerated with promising clinical benefits noted in various types of cancers.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 455

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 258

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 501

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 431

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 427

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 330

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 90

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 305

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 631

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring AI's Transformative Impact on Global Filmmaking

Updated Category News Views 171

The Future of Filmmaking in the Age of AI The Short Shorts Film Festival & Asia (SSFF & ASIA) recently hosted an engaging conference focused on how artificial intelligence is revolutionizing the filmmaking process. This Academy Award–qualifying festival has become a significant platform for showcasing short films from around the globe. During the event, titled 'The...

Continue Reading
Darkex Launches Revolutionary Crypto Trading Platform Today

Updated Category News Views 365

The Launch of the Darkex Cryptocurrency Trading Platform The long-awaited cryptocurrency exchange, Darkex, has officially launched, promising a top-notch trading experience for both retail and institutional investors. With a strong focus on security, innovation, and user-friendly services, Darkex aims to reshape the cryptocurrency trading landscape. Setting a New...

Continue Reading
Understanding the Saver's Credit: A Key to Retirement Savings

Updated Category News Views 187

The Importance of the Saver's Credit for Retirement Savers The Saver's Credit is a valuable resource for many individuals aiming to bolster their retirement savings while easing their tax burdens. Recent findings reveal that over half of U.S. workers remain unaware of this advantageous tax credit designed to aid retirement savers. Understanding this credit can empower...

Continue Reading
Why Stock Splits Matter: Insights on Major Tech Players

Updated Category News Views 190

Stock splits became a hot topic in the investment world during 2024, with companies like Nvidia and Sony Group making headlines. Traders were on high alert as these maneuvers shifted market dynamics. A stock split isn’t just a cosmetic change; it’s a tactical play that can signal confidence from management, but does it really move the needle for investors? Let’s...

Continue Reading
Accelerating Growth in Global Dry Film Photoresist Market

Updated Category News Views 177

Global Dry Film Photoresist Market Overview The dry film photoresist market is primed for substantial growth as it experiences increased demand across various industries. This market is characterized by its segmentation into types, namely positive and negative dry film photoresists, and applications including PCB manufacturing and semiconductor packaging. Projections...

Continue Reading